Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02143726 · ClinicalTrials.gov registry record · Phase 2
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
A Phase 2 study of Refractory Hurthle Cell Thyroid Cancer, sponsored by Alliance for Clinical Trials in Oncology.
- Active
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 20
- Study locations
NCT02143726 is a Phase 2 study of Refractory Hurthle Cell Thyroid Cancer that is active but no longer recruiting, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 35 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT02143726, a Phase 2 study of Refractory Hurthle Cell Thyroid Cancer, is active but no longer recruiting, sponsored by Alliance for Clinical Trials in Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase II trial studies the effects, good and bad, of using everolimus along with sorafenib tosylate versus sorafenib tosylate alone in treating patients with advanced radioactive iodine refractory thyroid cancer. Sorafenib tosylate and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of everolimus to sorafenib tosylate may cause more shrinkage of thyroid cancer and may prevent it from growing but it could also cause more side effects than sorafenib tosylate alone. It is not yet known whether this treatment with sorafenib tosylate and everolimus is better, the same, or worse than sorafenib tosylate alone.
Conditions Studied
Interventions
- DRUG sorafenib
- DRUG everolimus
Study Locations (20)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Sleepy Hollow - Sleepy Hollow
- Memorial Sloan Kettering Nassau - Uniondale
North Carolina
- Southeastern Medical Oncology Center-Clinton - Clinton
- Southeastern Medical Oncology Center-Goldsboro - Goldsboro
- Wayne Memorial Hospital - Goldsboro
- Southeastern Medical Oncology Center-Jacksonville - Jacksonville
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Florida
- Mayo Clinic in Florida - Jacksonville
Illinois
- Northwestern University - Chicago
Iowa
- Siouxland Regional Cancer Center - Sioux City
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2014-10-09 |
| Est. Completion | 2028-08-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02143726
The ClinicalTrials.gov registry entry for NCT02143726 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Refractory Hurthle Cell Thyroid Cancer appearing as the primary indexed condition, and to 2 interventions - of which sorafenib is the first listed.
NCT02143726 reports 20 study locations spanning 11 distinct geographic areas - top geographies include New York, North Carolina, New Jersey.
Frequently Asked Questions
What is clinical trial NCT02143726 about?
NCT02143726 is a clinical study titled "Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer". This randomized phase II trial studies the effects, good and bad, of using everolimus along with sorafenib tosylate versus sorafenib tosylate alone in treating patients with advanced radioactive iodine refractory thyroid cancer. Sorafenib tosylate and everolimus may stop the growth of tumor cells by...
What is the current status of trial NCT02143726?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2014-10-09. Estimated completion is 2028-08-06.
What conditions does trial NCT02143726 study?
This clinical trial studies the following conditions: Refractory Hurthle Cell Thyroid Cancer.
What interventions are being tested in trial NCT02143726?
The interventions under investigation include: sorafenib (DRUG), everolimus (DRUG).
Who is sponsoring clinical trial NCT02143726?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02143726 being conducted?
This trial has 20 study locations across Florida, Illinois, Iowa, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.